Screening for diabetic nephropathy: take your blinkers off

Authors

  • Ahmed Eid Department of Diabetes, University Hospitals of Leicester NHS Trust, Leicester, UK
  • Shafiq Yusuff Department of Diabetes, University Hospitals of Leicester NHS Trust, Leicester, UK
  • Marie-France Kong Department of Diabetes, University Hospitals of Leicester NHS Trust, Leicester, UK

DOI:

https://doi.org/10.15277/bjd.2018.174

Keywords:

screening, diabetic nephropathy, proteinuria, albuminuria, multiple myeloma

Abstract

Proteinuria is one of several markers of kidney damage in diabetes. The excretion of specific types of protein, such as albumin or low molecular weight globulins, depends on the type of kidney disease that is present.1 One of the earliest changes in diabetes is an increase in glomerular filtration rate (GFR), or hyperfiltration, which is observed in patients with type 1 as well as many with type 2 diabetes and is accompanied by an increase in renal size.2 The next observable change is the development of albuminuria, and current UK guidance recommends annual screening with the albumin creatinine ratio (ACR) to identify early kidney disease in patients with diabetes.3 Patients with diabetes with persistent microalbuminuria are at greatly increased risk for development of proteinuria (albuminuria >300 mg/day). However, it is important to exclude other causes of proteinuria in patients with diabetes, especially if there is no associated retinopathy. We report a case of an 81-year-old man with type 2 diabetes mellitus who presented with lower back pain and proteinuria but who had had normal/minimal microalbuminuria on his annual screening. He was diagnosed with multiple myeloma. The case highlights the importance of proteinuria in diagnosing multiple myeloma and the distinction between proteinuria in diabetic nephropathy and in multiple myeloma.

References

National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1–266.

Johnson RJ, ‎Feehally J, ‎Floege J. Comprehensive Clinical Nephrology. 5th edn. Philadelphia: Elsevier, 2015: Chapter 30.

National Institute for Health and Care Excellence. Chronic kidney disease in adults: assessment and management. NICE guideline [CG182]. 2014. https://www.nice.org.uk/guidance/cg182

Musso C, Javor E, Cochran E, et al. Spectrum of renal diseases associated with extreme forms of insulin resistance. Clin J Am Soc Nephrol 2006;1:616–22. http://cjasn.asnjournals.org/content/1/4/616.full

Redon J. Measurement of microalbuminuria: what the nephrologist should know. Nephrol Dial Transplant 2006;21:573–6. https://doi.org/10.1093/ndt/gfk014

Penno G, Solini A, Zoppini G, et al. Rate and determinants of association between advanced retinopathy and chronic kidney disease in patients with type 2 diabetes. Diabetes Care 2012;35:2317–23. https://doi.org/10.2337/dc12-0628

Mallette LE, Khouri K, Zengotita H, et al. Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume. J Clin Endocrinol Metab 1989;68:654.

Downloads

Published

2018-06-21

Most read articles by the same author(s)

1 2 > >>